Valuation dashboard for BioNTech SE (BNTX) with P/E N/A, P/B 1.18, EV/EBITDA -14.41 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
BioNTech SE, a biotechnology firm, specializes in the creation and marketing of immune-based treatments for malignancies and various infectious diseases. A significant part of its oncology pipeline includes the FixVac cancer vaccine program, which features several candidates in different phases of clinical development: BNT111 is in Phase 2 for advanced melanoma. BNT112 has reached Phase 1/2a for prostate cancer.
Analysis Summary
BioNTech SE reported revenue of $2.76B in the most recent fiscal year, growing at a 5-year CAGR of 41.7%.
Trailing-twelve-month margins: gross margin 68.9%, operating margin -64.6%, net margin -64.2%.
At the current price of $96.06, BNTX has negative trailing earnings (P/E not meaningful) and an ROE of -9.16%. Market capitalisation stands at $24.1B, placing it among large-cap names.
Balance sheet quality for BNTX: current ratio of 7.5. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 1.18 |
| EV / EBITDA | -14.41 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $47.30 |
| vs Current Price | -50.8% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| BNTX | BioNTech SE | $24.1B | 1.18 | -9.2% | |
| NTRA | Natera, Inc. | $52.5B | 29.06 | -11.7% | |
| BIIB | Biogen Inc. | $31.8B | 37.74 | 1.68 | 4.5% |
| DXCM | DexCom, Inc. | $33.7B | 34.51 | 13.08 | 36.2% |
| RPRX | Royalty Pharma plc | $26.0B | 24.23 | 3.80 | 11.9% |
| INCY | Incyte Corporation | $24.6B | 15.41 | 3.96 | 29.7% |
| GMAB | Genmab A/S | $21.1B | 27.13 | 3.58 | 16.5% |
| PHG | Koninklijke Philips N.V. | $24.1B | 18.54 | 1.81 | 10.0% |
Price
| Price | $96.06 |
| Market Cap | $24.1B |
| Exchange | NASDAQ |
| Country | DE |
Profitability
| Return on Equity | -9.16% |
| Return on Invested Capital | -9.25% |
| Return on Assets | -8.34% |
| Gross Margin | 68.95% |
| Operating Margin | -64.63% |
| Net Margin | -64.25% |
Related companies: BIIB · DXCM · GMAB · INCY · NTRA · PHG · RPRX
Explore sector: Healthcare · Biotechnology
More sections of BNTX: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks